Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07208058 | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) | PHASE3 | RECRUITING | 30 | — | — | Nov 21, 2025 | Nov 30, 2027 | Dec 2, 2025 | 15 | China |
| Arm | Type | Description |
|---|---|---|
| Plonmarlimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Plonmarlimab | DRUG | Subjects will receive Plonmarlimab 10 mg/kg by intravenous injection once weekly from Week 1 to Week 3, and Plonmarlimab 6 mg/kg by intravenous injection once weekly from Week 4 to Week 8 (10 mg/kg QW×3 + 6 mg/kg QW×5). |
Inclusion Criteria: * Age: 16 to 80 years (inclusive), of any gender. * The subject is willing to participate in this study and voluntarily signs the informed consent form. For minor subjects aged 16 years (inclusive) to less than 18 years, written informed consent must be signed by both the subjec...